Provides end-to-end revenue cycle management (RCM) services for hospitals and health systems. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 17% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $1.6B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 1,831.7× for every dollar this company earns in a year — a price that already assumes things go well.
Analysts' average target sits 20% above today's price.
The stock trades 53% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 17% a year on average.
The company’s market value is 1832 times its annual profit. Even a small disappointment could hit the price hard.
Since the drop from its peak, buyer appetite hasn’t come back.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.